Ligesom med andre anti- hiv- lægemidler risikerer patienter, der behandles med Isentress, at blive ramt af knoglevævsdød eller immunreaktiveringssyndrom (infektionslignende symptomer, der skyldes, at immunsystemet er ved at genvinde sin funktion).
As with other anti-HIV medicines, patients taking Isentress may be at risk of osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).